Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)โข Click on a phase to view related trials
Phase 1
1 (100.0%)Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
Recruiting
- Conditions
- Large B-cell LymphomaFollicular Lymphoma Grade 3APrimary Mediastinal Large B Cell LymphomaDiffuse Large B Cell LymphomaFollicular Lymphoma Grade 3B
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Pell Bio-Med Technology Co., Ltd.
- Target Recruit Count
- 49
- Registration Number
- NCT05377307
- Locations
- ๐จ๐ณ
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
๐จ๐ณChi Mei Medical Center, Tainan City, Taiwan
๐จ๐ณTaipei Medical University - Taipei Medical University Hospital, Taipei city, Taiwan
Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
Phase 1
Recruiting
- Conditions
- Primary Mediastinal Large B Cell LymphomaLarge B-cell LymphomaFollicular Lymphoma Grade 3AFollicular Lymphoma Grade 3BDiffuse Large B Cell Lymphoma
- Interventions
- Biological: CD19-targeted chimeric antigen receptor T-cell
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Pell Bio-Med Technology Co., Ltd.
- Target Recruit Count
- 49
- Registration Number
- NCT05326243
- Locations
- ๐จ๐ณ
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
๐จ๐ณChi Mei Medical Center, Tainan City, Taiwan
๐จ๐ณTaipei Medical University - Taipei Medical University Hospital, Taipei city, Taiwan
News
No news found